Q4 2025 Vanda Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Vanda Pharmaceuticals Inc (VNDA) reported a 24% increase in full-year net product sales for Fanapt, reaching $117.3 million, driven by a 28% rise in total prescriptions and a 149% surge in new-to-brand prescriptions.
- The company achieved a major regulatory milestone with the FDA approval of Nereus tradipitant for the prevention of vomiting induced by motion, marking the first new oral pharmacologic option in this space in over 40 years.
- Vanda Pharmaceuticals Inc (VNDA) anticipates total revenues of $230 million to $260 million in 2026 from its current marketed products, indicating continued growth.
- The company is preparing for the commercial launch of Nereus, which addresses an unmet need in motion sickness and has potential adjunct use in the expanding GLP-1 agonist market.
- Vanda Pharmaceuticals Inc (VNDA) is advancing its pipeline with several late-stage clinical programs, including a Phase III study of Bysanti for major depression and a Phase III program for iloperidone LAI for schizophrenia relapse prevention.
- Vanda Pharmaceuticals Inc (VNDA) reported a net loss of $220.5 million for the full year 2025, significantly higher than the $18.9 million net loss in 2024, primarily due to a one-time noncash income tax charge.
- HETLIOZ net product sales decreased by 7% to $71.4 million in 2025, impacted by ongoing generic competition in the US.
- The company experienced a $127.8 million increase in operating expenses, driven by higher SG&A expenses related to commercial launches and increased R&D expenses.
- Vanda Pharmaceuticals Inc (VNDA) is not providing 2026 cash guidance, but it is likely that the company's cash burn will be greater than in 2025.
- The Phase III program for iloperidone LAI is facing slower-than-expected enrollment due to delays in launching the study in Europe, impacting recruitment goals.
Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At time, I'd like to welcome Vanda Pharmaceuticals, Inc. earnings conference call. (Operator Instructions) Thank you. I'd now like to turn the call over to Kevin Moran, Vanda's Chief Financial Officer. Please go ahead.
Thank you, Jordan. Good afternoon and thank you for joining us to discuss Vanda Pharmaceuticals' fourth quarter and full year 2025 performance. Our fourth quarter and full year 2025 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer and Chairman of the Board; and Tim Williams, our General Counsel. Following my introductory remarks,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
